Nathan Rice

Stock Analyst at Piper Sandler

(3.13)
# 1,146
Out of 5,141 analysts
61
Total ratings
52.63%
Success rate
12.22%
Average return

Stocks Rated by Nathan Rice

Bank First
Jan 26, 2026
Maintains: Neutral
Price Target: $142$150
Current: $142.97
Upside: +4.92%
First Mid Bancshares
Nov 3, 2025
Maintains: Overweight
Price Target: $49$48
Current: $43.84
Upside: +9.49%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41$42
Current: $45.33
Upside: -7.35%
Byline Bancorp
Oct 28, 2025
Maintains: Overweight
Price Target: $34$35
Current: $33.13
Upside: +5.64%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $76.69
Upside: -3.51%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $161.37
Upside: -47.95%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $190.02
Upside: +3.67%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $24.98
Upside: -63.97%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $635.66
Upside: -31.57%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $280.31
Upside: -16.88%
Initiates: Neutral
Price Target: $83
Current: $43.24
Upside: +91.95%
Initiates: Overweight
Price Target: $15
Current: $20.57
Upside: -27.08%